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Abstract
Multidrug resistance (MDR) is a major barrier to the chemotherapy treatment of many cancers.
However, some non-ionic surfactants, for example Brij, have been shown to restore the sensitivity
of MDR cells to such drugs. The aim of this study was to explore the reversal effect of Brij on
MDR tumor cells and elucidate its potential mechanism. Our data indicate that the structure of Brij
surfactants plays an important role in overcoming MDR in cancer, i.e. modified hydrophilic-
lipophilic balance (MHLB, the ratio of the number (n) of hydrophilic repeating units of ethylene
oxide (EO) to the number (m) of carbons in the hydrophobic tail (CH2).). Cell viability of cells
treated with paclitaxel (PTX) nanocrystals (NCs) formulated with Brij showed positive
correlations with MHLB (R2 = 0.8195); the higher the ratio of Brij to PTX in NCs, the higher
cytotoxicity induced by the PTX NCs. Significant increases in intracellular accumulation of 3H-
PTX (P-gp substrate) were observed in an MDR cell line (H460/taxR cells) treated with Brij 78
(MHLB=1.11) and Brij 97 (MHLB=0.6). After treatments with Brij 78 and Brij 97, the levels of
intracellular ATP were decreased and verapamil induced ATPase activities of P-gp were inhibited
in multidrug resistant cells. The responses of the cells to Brij 78 and Brij 97 in ATP depletion
studies correlated with the cell viability induced by PTX/Brij NCs and intracellular accumulation
of 3H-PTX. Brij 78 and Brij 97 could not alter the levels of P-gp expression detected by western
blotting. These findings may provide some insight into the likelihood of further development of
more potent P-gp inhibitors for the treatment of MDR in cancer.
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INTRODUCTION
Multidrug resistance (MDR) is the leading cause of treatment failure in cancer therapy. One
of the most common mechanisms of MDR is drug efflux mediated by transporters such as P-
glycoprotein (P-gp), one of the most typical and the most widely investigated ATP-binding
cassette (ABC) transporters. P-gp can use the energy from ATP-hydrolysis to pump
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substrates like doxorubicin and paclitaxel (PTX) out of tumor cells, resulting in a reduction
of the accumulation of drugs in tumor cells.1, 2 To address this problem, P-gp inhibitors such
as verapamil, quinine and cyclosporin A have been introduced to reverse MDR since the
early 1980s. However, clinical trials have been disappointing due to the high inherent
toxicities of P-gp inhibitors and/or pharmacokinetic interactions between anticancer drugs
and inhibitors.
Non-ionic surfactants are extensively used in pharmaceutical formulations as solubilizers
and emulsifiers to improve dissolution and absorption of poorly soluble drugs. Several non-
ionic surfactants exhibited the ability to reverse P-gp-mediated MDR. For example, Pluronic
sensitizes MDR tumors by inhibiting the P-gp drug efflux system through ATP depletion.3-9
D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS, a water-soluble succinate ester
of vitamin E) is an amphiphilic compound consisting of a lipophilic (water-insoluble) α-
tocopherol portion and hydrophilic polar (water-soluble) PEG chain that can inhibit P-gp-
mediated drug efflux and increase the oral bioavailability of anticancer drugs.10-12 Our
laboratory has previously developed paclitaxel (PTX) nanocrystals (NCs) formulations using
TPGS as the sole excipient for overcoming MDR.13
Brij® molecules, commercially available nonionic surfactants, have also been shown to
inhibit efflux pumps. In a study by Lo (2003), Brij 30 significantly increased apical to
basolateral absorption and substantially reduced basolateral to apical efflux of epirubicin
across Caco-2 monolayers. The addition of Brij 30 also markedly enhanced mucosal to
serosal absorption of epirubicin in the rat jejunum and ileum.14 Similarly, Brij-35 effectively
enhanced bis (12)-hupyridone absorption in Caco-2 cells at a concentration lower than its
critical micelle concentration.15 Mumper et al. has prepared doxorubicin and paclitaxel-
loaded nanoparticles using Brij 78 as an emulsifying agent to overcome MDR by inhibiting
P-gp and depleting ATP.16 With these encouraging results, it was reasonable to assume that
other Brij molecules might produce similar or more efficient reversal of P-gp-mediated
MDR.
While the structures of all Brij molecules contain a polar head group consisting of PEG
chains with different lengths and a hydrophobic tail consisting of an alkyl chain, some
exhibit the ability to inhibit P-gp14-16 and others do not. Therefore, we hypothesized that the
structural properties of different Brij molecules may play a critical role in inhibiting P-gp. In
this study, we investigated PTX NCs formulations using a series of Brij surfactants to
identify structures or features required for overcoming MDR. Each Brij surfactant had
different PEG chain lengths and alkyl chain structures. The effects of different Brij
formulations on the physicochemical characteristics of NCs were also investigated. The
cytotoxicity of NCs against PTX resistant human lung carcinoma cell line (H460/taxR) was
examined by MTS assay. The P-gp function, intracellular ATP level, P-gp ATPase activity




Paclitaxel (PTX) was bought from Lc Laboratories (Woburn, MA). TPGS was bought from
Eastman (Anglesey, U.K.). Brij 700, Brij 78, Brij 98, Brij 97, Brij 52, Brij 72, Brij 30 and
Brij 35 were purchased from Sigma-Aldrich (St. Louis, MO). CellTiter 96® AQueous Non-
Radioactive Cell Proliferation Assay (MTS) were from Promega Corporation (Madison,
WI). H3-PTX was obtained from PerkinElmer Life Sciences. ATPlite™ Luminescence ATP
Detection Assay System was bought from PerkinElmer (Waltham, MA). Monoclonal
antibodies including the MDR1 (sc-55510), glyceraldehyde-3-phosphate dehydrogenase
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(GAPDH) (sc-20357) and the secondary antibody, anti-mouse or anti-rabbit IgG with HRP,
were products of Santa Cruz Biotechnology, Inc.
Tumor cell lines and cell culture
Resistant human lung cancer cell line H460/taxR was obtained from National Cancer
Institute. H460/taxR cells were maintained in RPMI-1640 medium supplemented with 10%
heated fetal bovine serum (Invitrogen, Carlsbad, CA), 100 U/mL penicillin, and 100 μg/mL
streptomycin (Invitrogen, Carlsbad, CA).
Preparation of NCs
The NCs were prepared through stabilization of the nanocrystals.17 PTX and TPGS or Brij
molecules were first dissolved in chloroform (in a glass tube) with different ratios (1:5, 1:3,
1:2, w:w) and coprecipitated by evaporating the chloroform with a steady flow of nitrogen
gas. A trace amount of chloroform was removed by keeping the precipitates under a vacuum
in a desiccator for 2 to 4 h. Following 20 min hydration in water and vortex, suspensions
were sonicated for 10 to 15 min in a bath-type sonicator (output 80 kC, 80 W) to form the
NCs.
Characterization of NCs
The particle size and distribution of NCs were measured using a submicron particle sizer
(NICOMP particle sizing systems, Autodilute-PAT model 370, Santa Barbra, CA) in the
NICOMP mode. Particle size and morphology were determined using a transmission
electron microscope (TEM) with an acceleration voltage of 100 kV. To prepare the samples,
PTX/Brij NCs (5 μL) were deposited onto a 200 mesh copper grid coated with carbon (Ted
Pella, Inc., Redding, CA) and allowed to stand for 5 min, excess liquid was then wicked off.
Samples were stained with 1% uranyl acetate (5 μL), followed by overnight air drying at
room temperature. Images were acquired using a JEOL 100CX II TEM.
Cytotoxicity on Resistant Cancer Cells
To evaluate cytotoxicity of PTX/TPGS or PTX/Brij NCs, an MTS ([3-(4, 5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)
assay was performed on H460/taxR cells. Cells were seeded into 96-well plates at a
concentration of 1 × 104 cells in a volume of 200 μL per well. After 24 h, various
formulations containing PTX were added, including PTX/TPGS NCs, PTX/Brij NCs, free
Brij and free PTX (the final paclitaxel concentration in the cell culture medium was 5 μM).
Free Brij was prepared using the methods to stabilize nanocrystals described above, but
without PTX. The free PTX dissolved in DMSO, free Brij and NCs were diluted using water
before being added to the medium. Following a 48 h period of incubation, the medium was
removed and 100 μL of fresh medium and 20 μL of the combined MTS/PMS solution was
added into each well of a 96-well assay plate. The plates were incubated for an additional 2
h at 37°C in a humidified, 5% CO2 atmosphere. The absorbance values were read on a
microplate reader using a Bio-Rad microplate imaging system (Hercules, CA) at a
wavelength of 490 nm. Cell viability was calculated using the following formula: cell
viability (%) (A490 nm for the treated cells/A490 nm for the control cells) × 100, where
A490 nm is the absorbance.
Cellular uptake of 3H-PTX in H460/taxR cells
H460/taxR cells were seeded in 24-well plates at a density of 1×105 cells per well and
incubated overnight. Confluent cell monolayers were treated with PTX or PTX/Brij NCs (5
μM PTX containing 32 nCi 3H-PTX per well) and incubated at 37 °C for 5 h. After
treatment, cells were washed three times with ice-cold PBS and lysed. The radioactivity in
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cell lysates was then quantified on a liquid scintillation analyzer (TRI-CARB, Packard
Bioscience Company, Waltham, MA). Celluar uptake efficiency of 3H-PTX (%) was
calculated by the amount of intracellular 3H-PTX/added 3H-PTX per well × 100.
Determination of intracellular ATP
The intracellular ATP content was measured by ATPlite™ Luminescence ATP Detection
Assay System with modifications from the manufacturer's protocol. Briefly, cells were
seeded in 96-well plates at a density of 1×104 cells per well and incubated overnight. Brij or
TPGS were added to cells and incubated at 37 °C for 2 h. After treatment, cells were washed
twice with ice-cold PBS and then an equal volume of the single-one-step reagent provided
by the kit was added to each well and rocked for 15 minutes at room temperature. Cellular
ATP content was measured by a luminescent plate reader.
P-gp ATPase assay
ATPase activity is potentially affected by Brij or TPGS; therefore, it was measured using a
P-gp-Glo™ assay system (Promega). The System provides the necessary reagents for
performing luminescent P-gp ATPase assays. These assays are valuable screening tools for
determining if a drug interacts with P-gp. The activity of P-gp ATPase is measured in the
presence or absence of Na3VO4 and Verapamil (positive reference). The assay method is
based on the dependence of ATP on the light-generating reaction of firefly luciferase. This
reaction is measured by detecting ATP consumption as a decrease in luminescence. The
effect of Brij on the ATPase activity of P-gp was measured using the manufacturer's
protocols. In a 96 well plate, recombinant human P-gp (25 μg) was incubated with P-gp-
Glo™ assay buffer (20 μl), verapamil (200 μM), sodium orthovanidate (100 μM), and test
compounds (Brij and TPGS at 50 μM). Each compound was loaded in five individual wells.
The reaction was initiated by the addition of MgATP (10 mM), then halted 40 min later by
the addition of 50 μL of the firefly luciferase reaction mixture (ATP detection reagent) that
initiated an ATP-dependent luminescence reaction. Signals were measured 60 min later
using a Bio-Rad microplate imaging system (Hercules, CA).
Western Blot Analysis
Total protein in the lysate was quantified using a Pierce BCA protein assay kit (Thermo
Scientific Inc., Rockford, IL). Approximately 40 μg of proteins from each sample were
separated by NuPAGE 12% gel and then transferred onto an Immobilon-P Transfer
Membrane (Millipore, Billerica, MA). The mouse monoclonal antibody to P-gp was used at
a 1:2000 dilution and the rabbit monoclonal anti-GAPDH clone at a 1:200 dilution. The
secondary antibodies used were an anti-mouse conjugated with HRP at a dilution of 1:10000
or an anti-rabbit IgG at a dilution of 1:2000. The specific protein bands were visualized
using a chemiluminescence kit (Pierce, Rockford, IL), and the chemiluminiscent signals
were detected with the use of high-performance chemiluminescence film (GE Healthcare).
Statistical analysis
All data were represented as mean value ± standard deviation (SD). Statistical comparisons
were made using a one-way analysis variance (ANOVA) Tukey's-test. Results were
considered significant when a confidence interval of 95% (p < 0.05) was achieved.
RESULTS
Characterization of NCs
The hydrophilic–lipophilic balance (HLB) concept was proposed by Griffin (1954) as
follows: “emulsifiers consist of a molecule that combines both hydrophilic and lipophilic
Tang et al. Page 4













groups and the balance of the size and strength of these two opposite groups is called HLB.
For the purpose of convenience, the effective balance of these groups is assigned a numeric
value.” For the polyoxyethylene alkyl ethers and polyoxyethylene esters, Griffin considered
the chain unities of ethylene oxide as the hydrophilic group. According to Griffin,
HLB=20*Mh/M, where Mh is the molecular mass of the hydrophilic portion of the molecule,
and M is the molecular mass of the whole molecule.18
The structures, composition, and HLB of the different Brij molecules are shown in Table
1.19 PTX/Brij NCs can be formed when the Brij has an HLB ≥ 9 at a ratio of 1:5, w:w or an
HLB ≥ 15 at ratios of 1:3 and 1:2, w/w. PTX/Brijs NCs can be formed at ratios from 1:2-1:5
when MHLB (the ratio of the number (n) of hydrophilic repeating units of ethylene oxide
(EO) to the number (m) of carbons in the hydrophobic tail (CH2)) of Brij is greater than 0.3.
The stable NCs could not be formulated with Brij 52 and Brij 72 with 2 PEG repeating units
(formation of aggregates). Therefore, they were not selected for the further study. Brij 700
with highest HLB and PEG repeating units (n=100) formed NCs of the smallest particle size
(Table 2). PTX/Brij NCs with PTX:Brij ratios of 1:2 are significantly larger than NCs with a
ratio of 1:5, but the morphology of both was rod-shaped (Figure. 1).
Effect on Resistant Cancer Cells in Vitro
The antiproliferation effect of various formulations of PTX on H460/taxR cells that
overexpress P-gp and are resistant to PTX, were measured by MTS. Data (Figure. 2) were
compared using an ANONA and Tukey's-test, which showed a significant difference (p <
0.05) between PTX/TPGS, PTX/Brij 58, PTX/Brij 78, PTX/Brij 98, PTX/Brij 97, PTX/Brij
S10, PTX/Brij 30 NCs and the free PTX (Figure. 2A). PTX/Brij 58, 78 and 98 NCs with the
ratio of 1:5 (w:w) exhibited an enhanced anti-proliferation effect similar to that of PTX/
TPGS, which inhibited cell growth by 40%. The free Brij 58, 78 and 98 were virtually
ineffective (Figure. 2B). There was a significant difference (p < 0.05) between the group of
free Brij 30 (1:5), Brij S10 (1:5-1:3), Brij 97 (1:5) and the negative control (DMSO).
Notably, PTX/Brij 30 NCs with a ratio of 1:5 (w:w) exhibited an enhanced antiproliferation
effect similar to that of PTX/Brij 78 and 97 NCs, which could be the result of the cytotoxicy
of free Brij 30 (Figure. 2B). Cell viability for PTX/Brij 30 NCs was 48.0%, but it was 69.3%
for free Brij 30.
When the data are re-plotted with MHLB on the x-axis and percentage of cell viability (from
Figure 2) on the y-axis, a positive correlation is shown between MHLB of Brij surfactants
and viability with a coefficient (R2) of 0.8195. Cell viability of PTX/ Brij NCs was more
related to MHLB than HLB (Figure 3). This observation suggests that Brij molecules with a
lower ratio of MHLB show a stronger ability to overcome MDR. Although Brij 35 has a
similar HLB to Brij 58, 78 and 98, PTX/Brij 35 NCs did not significantly inhibit cell
growth. The composition of Brij 35 contains fewer hydrophobic repeating units (m=12),
potentially causing its ineffectiveness. PTX NCs of Brij 700 and Brij 35 with the ratio of 1:5
(w/w) containing a ratio of hydrophilic repeating units to hydrophobic repeating units
(MHLB) > 1.5 were also ineffective in reversing the resistance of H460/taxR to PTX (Figure
3).
Cellular uptake of 3H-PTX in H460/taxR cells
The cellular uptake of 3H-PTX in the presence of Brij 78, 97, 30, 35 and TPGS was also
determined in H460/taxR cells. Brij 78, 97 and TPGS increased the intracellular uptake
of 3H-PTX by 4.5-, 7.6- and 3.4-fold in H460/taxR cells, respectively. Brij 30 and 35 had
less effect on intracellular uptake of 3H-PTX (Fig. 4A). However, PTX/Brij 30 NCs with a
ratio of 1:5 (w:w) exhibited an enhanced antiproliferation effect similar to that of PTX/Brij
78 and 97, which could be the result of the cytotoxicity of free Brij 30 (Fig. 2B). Brij 78, 97
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and TPGS increased the uptake of 3H-PTX in H460/taxR cells significantly, suggesting that
these could inhibit P-gp.
Determination of intracellular ATP and P-gp expression
Because drug efflux is an energy-dependent process, the intracellular ATP levels of cells
after they are treated with Brij 78, 97, 30 and 35 without loading drugs were investigated.
We found that exposing cells to Brij 78 and 97 could induce a significant decrease in ATP in
drug resistant cells (p < 0.05, Fig. 5A). Brij 78 and 97 are more active in the process of ATP
depletion and displayed higher efficacy in sensitizing the cytotoxic activity of the drugs in
resistant cells. On the contrary, Brij 30 and 35 are less active in ATP depletion are also the
least efficacious in sensitizing the drug cytotoxic activity.
Nanoparticles can also protect loaded drugs from efflux by P-gp. The reversal of P-gp
mediated MDR can usually be achieved either by down-regulating P-gp expression or
inhibiting its function. To assess the effect of P-gp protein expression levels, Western blot
analyses were performed. After pretreatment by Brij 78, 97 and TPGS (in the same
concentration as cytotoxicity), the expression level of P-gp protein (Fig. 5B) was not
significantly altered compared to the control in H460/taxR cells. The results indicate that
inhibiting the expression of P-gp is not involved in the reversal of P-gp MDR by Brij78, 97
or TPGS.
P-gp ATPase activity
Drug stimulated P-gp ATPase activity was estimated by P-gp-Glo assay system (Promega,
Madison, WI) and the results were shown in Figure 6. This method relies on the ATP
dependence of the light-generating reaction of firefly luciferase, where ATP consumption is
illustrated as a decrease in luminescence; the greater the decrease in signal the higher the P-
gp activity. Sodium orthovanadate was used as a P-gp ATPase inhibitor, whereas Verapamil
was used as a positive control. Test compounds that are significantly lower than the control
(NT) are P-gp substrates, whereas test compounds that are significantly higher than the NT
are P-gp inhibitors. Data were compared using an ANOVA and Tukey's-test. Brij 78, 97 and
TPGS (all tested at 50 μM) did not significantly influence ATPase activity on their own (p >
0.05). None induced additional ATPase activity nor inhibited basal ATPase function (Fig.
6A). However, in the presence of Verapamil (200 μM), which stimulated ATPase activity;
Brij 78, 97 and TPGS were able to significantly inhibit Verapamil-induced ATPase activity
(p < 0.05, Fig. 6B).
DISCUSSION
MDR is a major clinical problem that significantly reduces the efficacy of many
chemotherapeutic agents. The most extensively studied mechanism of MDR is the
overexpression of P-gp as cell surface efflux pumps that can successfully purge a wide
spectrum of chemotherapeutic agents from cells, thereby decreasing their intracellular
accumulation and creating resistance. The inhibition of P-gp in order to reverse MDR in
cancer cells has been studied extensively. In addition to small molecule inhibitors,
surfactants such as several Pluronics and TPGS are known to modulate efflux pump activity.
The therapeutic nanoparticles have emerged as an innovative and promising alternative over
conventional small molecule chemotherapeutics aimed at specifically targeting the
therapeutic payload to tumors and overcoming MDR.20-26 Previous work conducted in our
laboratories demonstrated that PTX NCs prepared using TPGS as the sole excipient can
overcome the drug-resistance in human ovarian NCI/ADR-RES cancer cells. We are able to
compare TPGS and Brij molecules because of their similarities; both TPGS and Brij have
linear amphiphilic structures with varying lengths of PEG creating the hydrophilic head and
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varying lengths of linear hydrocarbon tails. We hypothesize that the structure of nonionic
surfactants may be crucial to overcoming MDR.
Brij surfactants have different molecular structures, some of which have been reported to be
P-gp inhibitors. Therefore, the Brij surfactants (see Table 1 for their structures, compositions
and HLB19) had been systemically explored in the present study. The cytotoxicity of various
formulations of PTX/Brij NCs on H460/taxR cells, which overexpress P-gp and are resistant
to PTX are summarized in Figure 2. A Brij molecule with a lower ratio of MHLB shows a
greater ability to inhibit P-gp, resulting in the higher cytotoxicity of PTX/Brij. Tween
(Tween 20, 40 and 80) and DSPE-PEG have also been included in our studies. However,
while paclitaxel (PTX) can be formulated into NCs with Tween and DSPE-PEG surfactants,
these surfactants did not show the activity required to overcome MDR (data not shown).
Previously we studied PTX/F127 (pluronic F127) and PTX/TPGS nanocrystals.13 PTX/
TPGS nanocrystals can overcome MDR, but PTX/F127 nanocrystals cannot, despite the fact
that both crystals are rod shaped. These observations lead us to the conclusion that the shape
of the NPs has very little to do with MDR. The reason we used nanocrystals is their high
PTX loading efficiency and their structural simplicity (nanocrystals only require one type of
non-ionic surfactant as an excipient, which has advantages in completing mechanism
studies).
When compared with some Brij molecules, Tween surfactants are shown to have the same
hydrophobic tails, for example, Tween 60 compared to Brij 78 and S10 or Tween 80
compared to Brij 97 and 98. However, the hydrophilic portions of the two molecule types
are different. Brij molecules have a linear PEG chain as their hydrophilic region, whereas
Tween has three branched, shorter PEG chains. Consequently, Brij molecules show a
significant inhibition of P-gp and Tween surfactants do not. Collnot et al. (2007) revealed
that the rate of permeation of rhodamine 123 (a P-gp substrate) through monolayers of
Caco-2 cells was strongly influenced by the length of PEG chains, with an optimum
molecular weight of these linear PEG chains occurring between 1000 and 1500 Da.11
Therefore, we conclude that the hydrophilic head group of Tween does not play an
important role in inhibiting P-gp. This finding provides some insight into the role of the
structures of Brij-based surfactants in overcoming MDR, which is useful for synthesizing or
screening new P-gp inhibitors.
Reduction of the intracellular concentration of chemotherapeutic agents is a major cause of
MDR. It is a widely held hypothesis that intracellular levels of anticancer drugs are reduced
below lethal thresholds by active extrusion through the operation of ATP-dependent pumps
such as P-gp.27 Thus, the activity of P-gp can be studied by measuring the transportation of
P-gp substrates. In our study, we found that Brij 78, Brij 97 increased the accumulation
of 3H-PTX in P-gp overexpressed MDR cells. These dates were consistent with our
cytotoxic results, collectively suggesting that Brij 78, Brij 97 can inhibit the transport
function of P-gp, increasing the intracellular concentration of its substrate anticancer drugs.
The increased accumulation of intracellular drugs may be a result of the decreased
expression of P-gp or decreased function of P-gp. Since incubation of MDR cells with Brij
78 or Brij 97 up to 48 h did not significantly change the expression levels of P-gp protein, it
is unlikely that Brij 78 or Brij 97 reverses P-gp-mediated MDR.
The exact mechanism by which excipients inhibit efflux transporters remains unknown.
Pluronic P85 has been reported to significantly reduce intracellular ATP levels, and this
correlates with the inhibition of efflux transporters.28 The mechanism of inhibition of the
cellular efflux pumps by TPGS involves inhibition of ATPase rather than a competitive
inhibition or a nonspecific effect on the fluidity of the cell membrane.10-12 For example,
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TPGS 1000 is similar to polyoxyethylene (40) stearate (Myrj 52), a material known to affect
P-gp ATPase while not influencing intracellular ATP or mitochondrial function. As a result,
there does not appear to be a common inhibitory mechanism for all nonionic surfactants; the
interaction with P-gp needs to be investigated for each individual surfactant until a broader
relationship between structure and inhibition is defined.
It is quite possible that the chemosensitization phenomenon is a direct result of the decrease
in the ATP pools available within the drug resistant cells. In our results, there is a clear
correlation between the levels of uptake of P-gp substrate, H3-PTX, and the ATP levels in
the P-gp overexpressing H460/taxR cells after treatment by Brij78 and Brij 97. Brij 78 could
also enhance doxorubicin uptake and decrease the efflux and depletion of ATP after NCI/
ADR-RES cells were pretreated with various concentrations of Brij 78.16 Our results
indicated that TPGS did not deplete ATP significantly, which is in accordance with the
research performed by Dong (2009).16 Brij 30 increased the uptake of mitoxantrone, but it
did not change the intracellular ATP levels in the P-gp/MDCK-II cells.29 In the present
study, Brij 30 did not reduce the intracellular ATP levels and produced only a minor
increase in the intracellular accumulation of 3H-PTX in H460/taxR cells, which is
contradictory to previous findings.14, 29 However, this might be because of a difference in
the cell lines used. Furthermore, the expression level of P-gp was not affected by the
treatments with the addition of Brij78 and Brij 97 (in the same concentration as
cytotoxicity).
P-gp has an ATP-binding region that is essential for substrate transport and the hydrolysis of
ATP by P-gp ATPase is critical for restoring the transporter to its active conformational
state. Thus, monitoring ATPase activity in cell membrane preparations or in purified
membrane proteins allows for identification of those compounds that interact with the drug
efflux transporters. P-gp exhibits a highly drug-dependent ATP hydrolysis activity, and a
variety of P-gp inhibitors, as well as P-gp substrates, can stimulate ATPase activity.30 When
incubated on their own with artificial P-gp containing membranes (Fig. 6A), Brij78, Brij 97
and TPGS neither stimulated ATPase activity nor inhibited basal ATPase function at the
concentration 50 μM. These results indicate that there is no direct interaction between the
transport sites and the surfactants. Brij78, Brij 97 and TPGS therefore appeared not to be a
substrate of P-gp, making a competitive inhibition of substrate binding unlikely. However, a
significant inhibition of P-gp after Verapamil-induced ATPase activation was indeed
observed.
CONCLUSION
This study identified structures or features required for overcoming MDR and provided the
first in vitro evidence that Brij 78 and Brij 97 decreased intracellular ATP levels (energy
depletion) and inhibited Verapamil-induced ATPase activity of P-gp in multidrug resistant
cells. The combination of these two effects is essential for inhibition of P-gp drug efflux
system and chemosensitization of these cells. In addition, the Brij or TPGS did not affect the
protein expression of P-gp. Further understanding of the mechanisms of the Brij effects will
be crucial for the successful development and use of Brij formulations to improve
chemotherapy of resistant tumors in the future.
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Transmission electron microscope images of PTX/Brij 78 nanocrystals with the ratio of 1:2
(A) and 1:5 (B) (w:w).
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H460/taxR cell viability after being treated with PTX/Brij or PTX/TPGS nanocrystals with
ratios of 1:5, 1:3 and 1:2 (w:w) for 48 h, and free PTX at a concentration of 5 μM (n=6). (A)
PTX/TPGS, PTX/Brij nanocrystals and free PTX. * indicates significant difference
compared to PTX (in DMSO) at p <0.05. (B) Free TPGS or Brij. Free Brij or TPGS were
prepared by the method of SNC without PTX. * indicates significant difference compared to
DMSO at p <0.05.
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The relationship between the MHLB (A) or HLB (B) of Brij molecules and cell viability of
H460/taxR cells after treatment with PTX/Brijs NCs. Points, mean; bars, SD (n=6).
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The effects of Brij and TPGS on cellular uptake of 3H-PTX in H460/taxR cells. H460/taxR
cells were treated with free PTX or PTX/Brijs nanocrystals (5 μM PTX containing 32
nCi 3H-PTX per well) and incubated at 37 °C for 5 h. Cellular uptake efficiency of 3H-PTX
(%) was calculated by the amount of intracellular 3H-PTX/added 3H-PTX per well × 100. *
indicates significant difference compared to the control at p <0.05. Data are represented as
the mean ± SD (n=3).
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(A) The effects of Brij and TPGS on intracellular ATP levels in H460/taxR cells. Data are
represented as the mean ± SD (n=5). * indicates significant difference compared to the
control at p <0.05. (B) The effects of Brij and TPGS on P-gp expression by western blotting.
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(A) The effects of Brij and TPGS on P-gp ATPase in H460/taxR cells. * indicates
significant difference from the control at p <0.05. (B) The effects of Brij and TPGS on
Verapamil induced ATPase activity. * indicates significant difference from verapamil at p
<0.05. Brij and TPGS at 50 μM. Data are represented as the mean ± SD (n=5).
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Table 2
The particle size and distribution of PTX/Brij nanocrystals (PTX/Brij=1:5, w/w)
Size (nm) PDI Zeta (mV)
PTX/Brij 72 n/a n/a n/a
PTX/Brij 52 n/a n/a n/a
PTX/Brij 30 104.4 0.256 -24.3
PTX/Brij S10 142.7 0.194 -9.7
PTX/Brij 97 244.7 0.513 -15.7
PTX/Brij 78 144.4 0.258 -11.7
PTX/Brij 58 228.7 0.216 -12.9
PTX/Brij 98 79.12 0.209 -12.5
PTX/Brij 35 66.84 0.187 -23.7
PTX/Brij 700 77.70 0.229 -8.47
n/a: not available
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